価格の低さにかかわらず,レジナノンの株は700. 64ドルに急上昇し,76.99Bの市場キャップを維持した. Despite lowered price targets, Regeneron's stock surged to $700.64, maintaining a $76.99B market cap.

最近,TD Cowen,BMO Capital Markets,Leerink Partnersなど,レジェノン製薬 (REGN) の価格目標を下げたアナリストも数多くいますが,評価は引き続き良好です. Several analysts have recently lowered their price targets for Regeneron Pharmaceuticals (REGN), including TD Cowen, BMO Capital Markets, and Leerink Partners, though ratings remain positive. 価格の削減にもかかわらず,レガネーション株式は700.64ドルに増加した. Despite the price target reductions, Regeneron's stock saw an increase to $700.64. この会社は 黄斑変性などの病気の治療法を開発していることで知られています 市場総額は769.9億ドルで 主に機関投資家が所有しています The company, known for developing treatments for diseases like macular degeneration, has a market cap of $76.99 billion and is primarily owned by institutional investors.